Progress of biological mechanism of immune checkpoint inhibitors and their applications in treatment of lymphoma
10.3760/cma.j.cn115356-20200820-00206
- VernacularTitle:免疫检查点抑制剂的生物学机制及在淋巴瘤治疗中的研究进展
- Author:
Ting ZHANG
;
Huaqing WANG
- From:
Journal of Leukemia & Lymphoma
2021;30(2):122-125
- CountryChina
- Language:Chinese
-
Abstract:
Malignant lymphoma is a common malignant tumor of the lymphatic system. In recent years, immunotherapy is a new direction in the field of lymphoma treatment after targeted therapy, radiotherapy and chemotherapy. Immune checkpoint inhibitors (ICPi) have achieved significant efficacy in Hodgkin lymphoma (HL), with an overall response rate of about 80%, which makes the clinical application of ICPi in patients with malignant lymphoma become the focus of attention. This article reviews the recent progress in the biological mechanism of programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen (CTLA-4), and the application of ICPi in the treatment of HL and non-Hodgkin lymphoma.
